Prospective randomized trial of angiotensin receptor neprilysin inhibitor addition after ablation for atrial fibrillation with hypertension

Prospective randomized trial of angiotensin receptor neprilysin inhibitor addition after ablation for atrial fibrillation with hypertension - Prospective randomized trial of angiotensin receptor neprilysin inhibitor addition after ablation for atrial fibrillation with hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046613

Enrollment

200

Registered

2022-01-13

Start date

2022-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation with hypertension

Interventions

In the intervention group, the antihypertensive drug is changed to an angiotensin receptor neprilysin inhibitor (ARNI) after ablation treatment. The control group will continue with conventional antih

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atrial fibrillation in patients with hypertension who undergo catheter ablation for atrial fibrillation. All patients are treated with oral anti-coagulants before the procedure.

Exclusion criteria

Exclusion criteria: Patients who are intolerant for ARNI Patients with renal insufficiency (estimated GFR < 30) Patients with systolic blood pressure <100 mmHg When the attending physician consider inappropriate to enroll the patient in the study

Design outcomes

Primary

Measure	Time frame
Primary outcome is recurrence of atrial fibrillation at 12-month after catheter ablation.	—

Secondary

Measure	Time frame
1) Atrial fibrillation recurrence rate (1,3,6,12 months after surgery) 2) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 3) Changes in systolic and diastolic blood pressure from baseline (1, 3, 6, 12 months after surgery) 4) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, Nt-proBNP, galectin3 5) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left atrium function: Booster function, Reservoir function, Conduit function, Atrial ejection force Left atrium diameter, left atrium volume Left ventricular expandability: E / e` ratio Left ventricular ejection fraction (LVEF) Velocity time integral (VTI) 6) Moyamoya echo, left atrial appendage blood flow velocity (within 48 hours before catheter ablation) 7)ratio of low potential region in the left atrium (during catheter ablation) in 2nd ablation at the time of recurrence (during catheter ablation) 8) Change in cardiothoracic ratio from baseline by chest X-ray (12 months after surgery)	—

Measure

Time frame

1) Atrial fibrillation recurrence rate (1,3,6,12 months after surgery) 2) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 3) Changes in systolic and diastolic blood pressure from baseline (1, 3, 6, 12 months after surgery) 4) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, Nt-proBNP, galectin3 5) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left atrium function: Booster function, Reservoir function, Conduit function, Atrial ejection force Left atrium diameter, left atrium volume Left ventricular expandability: E / e` ratio Left ventricular ejection fraction (LVEF) Velocity time integral (VTI) 6) Moyamoya echo, left atrial appendage blood flow velocity (within 48 hours before catheter ablation) 7)ratio of low potential region in the left atrium (during catheter ablation) in 2nd ablation at the time of recurrence (during catheter ablation) 8) Change in cardiothoracic ratio from baseline by chest X-ray (12 months after surgery)

—

Countries

Japan

Contacts

Public ContactMorio Ono

Showa University Northern Yokohama Hospital Cardiology

morio.ono@gmail.com(+81)45-949-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026